靶向间皮素的肿瘤治疗生物技术药物研究进展

间皮素是主要由间皮细胞表达的一类糖蛋白，间皮细胞主要分布于人体的腹膜、胸膜及心包等组织中，而在其他组织中分布较少。近年来多个研究发现，间皮素在卵巢癌、肺癌、胰腺癌及间皮瘤等多种恶性肿瘤细胞中高表达，间皮素在正常组织中分布较少而在肿瘤组织中分布较多的这一特性使得间皮素成为了治疗相关肿瘤的十分具有潜力的靶标。生物大分子靶向药物相比于传统小分子药物安全性更好，因而具有广泛的应用前景。药物类型主要包括免疫毒物偶联物、单抗及抗体药物偶联药物等。综述了间皮素的功能及其在肿瘤中的表达情况，并对目前在研的靶向间皮素的生物技术药物研究进展进行了概述。

Molecular cloning of mesothelin,a differentiation antigen present on mesothelium,mesotheliomas, and ovarian cancers

Mesothelin is a glycoprotein expressed mainly on some normal mesothelial cells lining the pleura, pericardium and peritoneum with limited expression on other normal tissues. Many studies in recent years have found that it is overexpressed in multiple cancers including ovarian cancers, lung cancers, pancreatic cancers and mesothelioma, so mesothelin is a promising candidate target for tumor-specific therapy. Macromolecular drugs have broader prospect of application with their superiority in safety in comparison with traditional small molecular drugs. Main types of macromolecular drugs include immune toxins, mono-antibody and antibody drug conjugates. This paper briefly reviews the target expression and function of mesothelin as well as the development progress of some mesothelin targeted biologics.